Skip to main content

Pyoderma

3
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
sisomicinPhase 41 trial
Active Trials
NCT00202891Withdrawn0Est. Sep 2007
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
sisomicinPhase 4
JSC Valenta Pharmaceuticals
1 program
1
HydroxymethylquinoxalindioxydePhase 31 trial
Active Trials
NCT05561816Completed240Est. Dec 2022
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
sisomicinPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDsisomicin
JSC Valenta PharmaceuticalsHydroxymethylquinoxalindioxyde

Clinical Trials (2)

Total enrollment: 240 patients across 2 trials

Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)

Start: May 2007Est. completion: Sep 20070
Phase 4Withdrawn
NCT05561816JSC Valenta PharmaceuticalsHydroxymethylquinoxalindioxyde

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Start: Jul 2022Est. completion: Dec 2022240 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.